Physician profile
Paul Kendall Edwards
NPI 1235289596
$158,015.17
in general payments reported to CMS, 2019-2025
11 companies · $62K in 2025
The $62K reported for 2025 was more than what 89% of Adult Reconstructive Orthopaedic Surgery providers received nationally (typical 2025 total: $1,425).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $7,207 · 2021: $8,533 · 2022: $10K · 2023: $18K · 2024: $31K · 2025: $62K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $53K · Royalty Or License: $22K · Consulting Fee: $16K · Travel and Lodging: $16K · Food and Beverage: $3,679.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $52,998.34 |
| Royalty Or License | $21,852.73 |
| Consulting Fee | $16,125.00 |
| Travel and Lodging | $16,036.42 |
| Food and Beverage | $3,678.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $89,866.66 | 2019-2025 | Arcos, Avenir, G7 |
| Encore Medical, Lp | $65,106.46 | 2019-2025 | Djo Surgical |
| Heron Therapeutics, INC. | $2,122.02 | 2019 | |
| Paragon 28, INC. | $228.80 | 2021 | |
| Stryker Corporation | $203.86 | 2019-2025 | Gamma |
| Exactech, INC. | $132.04 | 2019 | |
| Depuy Synthes Sales INC. | $116.87 | 2021 | |
| Medacta USA, INC. | $107.06 | 2022 | |
| Midsouth Orthopedics INC. | $99.37 | 2024 | |
| Pacira Pharmaceuticals Incorporated | $26.43 | 2024 | Iovera |
| Kinex Medical Company LLC | $5.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.